Salmon clotting proteins for human bandages

Fibrin bandages have shown considerable promise in controlling traumatic bleeding. However, two significant problems are cost, and the possibility of infectious agents.Our overall objective is to solve both problems with the use of fibrinogen and thrombin from salmon plasma. Phase II aim are to 1. Develop a formulation that is stable without refrigeration. 2. Demonstrate the level of immunogenicity. 3. Determine thechemical and functional equivalence of human and salmon fibrinogen and thrombin. 4. Prepare a prototype bandage for animal trials.Salmon clotting proteins are compatible with human proteins, and are likely to be less expensive due to the large untapped blood supply from farmed fish. Evolutionary distance and the low body temperature of the salmon point to safety from mammalianinfectious agents.We will follow FDA guidelines for further stability and viral inactivation work that will lead to a clinical formulation of the proteins. These formulations will be used for immunogenicity and toxicology studies, and applied to a prototype bandage.Salmon clotting proteins offer an effective, innovative material for human use that is likely to be safer and less costly than human material. The anticipated benefits ofthe proposed work are a safer and less costly bandage for human use